ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Target Price of $25.00 According to Brokerages

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $25.00.

SPRY has been the topic of several recent research reports. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, September 8th. Weiss Ratings lowered ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $4.36 on Thursday. The firm has a market cap of $433.60 million, a P/E ratio of -2.00 and a beta of 0.85. The company has a current ratio of 3.48, a quick ratio of 3.28 and a debt-to-equity ratio of 13.72. ARS Pharmaceuticals has a 1-year low of $3.98 and a 1-year high of $13.15. The business’s 50 day moving average is $5.17 and its 200-day moving average is $7.15.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%.The firm had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. Equities research analysts predict that ARS Pharmaceuticals will post -1.9 earnings per share for the current year.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bessemer Group Inc. boosted its holdings in shares of ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock valued at $61,000 after purchasing an additional 7,290 shares in the last quarter. Alpine Woods Capital Investors LLC bought a new position in ARS Pharmaceuticals in the first quarter valued at about $80,000. Syon Capital LLC acquired a new position in ARS Pharmaceuticals during the second quarter worth about $80,000. Allianz Asset Management GmbH acquired a new stake in shares of ARS Pharmaceuticals in the 2nd quarter valued at approximately $82,000. Finally, Foster & Motley Inc. bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter valued at approximately $118,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product, neffy, is an epinephrine nasal spray designed to provide a needle-free alternative to injectable epinephrine for the emergency treatment of type I allergic reactions, including anaphylaxis.

Neffy received approval from the U.S. Food and Drug Administration in 2024 for adults and children who meet the applicable weight requirements.